This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ergun-Longmire, B. Articles by Sklar, C. A. Search for Related Content PubMed PubMed Citation Articles by Ergun-Longmire, B. Articles by Sklar, C. A. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology Endocrine Oncology

Growth Hormone Treatment and Risk of Second Neoplasms in the Childhood Cancer Survivor

Department of Pediatrics (B.E.-L.), New York Presbyterian Hospital, Weill Medical College of Cornell, New York, New York 10021; Department of Pediatrics (A.C.M., P.M.), University of Minnesota School of Medicine, Minneapolis, Minnesota 55455; Departments of Epidemiology and Biostatistics (J.Q., G.H., W.S.), Memorial Sloan-Kettering Cancer Center, New York, New York 10021; Department of Public Health Sciences (Y.Y.), University of Alberta, Edmonton, Alberta, Canada, T6G 2G3; Department of Epidemiology and Cancer Control (L.L.R.), St. Jude Children’s Research Hospital, Memphis, Tennessee 38105; and Department of Pediatrics (C.A.S.), Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Address all correspondence and requests for reprints to: Charles A. Sklar, M.D., Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021. E-mail: sklarc{at}mskcc.org.

Context: GH deficiency is common in childhood cancer survivors. In a previous report, although we did not find an increase in the risk of disease recurrence in survivors treated with GH, GH-treated survivors did have an increased risk of developing a second neoplasm (SN) (rate ratio, 3.21).

Objective: In this analysis, we have reassessed the risk of GH-treated survivors developing an SN after an additional 32 months of follow-up.

Design and Setting: We conducted a retrospective cohort multicenter study.

Patients: Among a total of 14,108 survivors who were enrolled in the Childhood Cancer Survivor Study, a retrospective cohort of 5-yr survivors of childhood cancer, we identified 361 who were treated with GH.

Main Outcome: We assessed the risk of developing an SN.

Results: During the extended follow-up, five new SN developed in survivors treated with GH, for a total of 20 SN, all solid tumors. Using a time-dependent Cox model, the rate ratio of GH-treated survivors developing an SN, compared with non-GH-treated survivors, was 2.15 (95% confidence interval, 1.3–3.5; P < 0.002). Meningiomas were the most common SN (n = 9) among the GH-treated group.

Conclusion: Although cancer survivors treated with GH appear to have an increased risk of developing SN compared with survivors not so treated, the elevation of risk due to GH use appears to diminish with increasing length of follow-up. Continued surveillance is essential.

This article has been cited by other articles:

				M. M. Hudson, D. A. Mulrooney, D. C. Bowers, C. A. Sklar, D. M. Green, S. S. Donaldson, K. C. Oeffinger, J. P. Neglia, A. T. Meadows, and L. L. Robison High-Risk Populations Identified in Childhood Cancer Survivor Study Investigations: Implications for Risk-Based Surveillance J. Clin. Oncol., May 10, 2009; 27(14): 2405 - 2414. [Abstract] [Full Text] [PDF]

				L. Diller, E. J. Chow, J. G. Gurney, M. M. Hudson, N. S. Kadin-Lottick, T. I. Kawashima, W. M. Leisenring, L. R. Meacham, A. C. Mertens, D. A. Mulrooney, et al. Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings J. Clin. Oncol., May 10, 2009; 27(14): 2339 - 2355. [Full Text] [PDF]

				L. L. Robison, G. T. Armstrong, J. D. Boice, E. J. Chow, S. M. Davies, S. S. Donaldson, D. M. Green, S. Hammond, A. T. Meadows, A. C. Mertens, et al. The Childhood Cancer Survivor Study: A National Cancer Institute-Supported Resource for Outcome and Intervention Research J. Clin. Oncol., May 10, 2009; 27(14): 2308 - 2318. [Abstract] [Full Text] [PDF]

				R. Mody, S. Li, D. C. Dover, S. Sallan, W. Leisenring, K. C. Oeffinger, Y. Yasui, L. L. Robison, and J. P. Neglia Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study Blood, June 15, 2008; 111(12): 5515 - 5523. [Abstract] [Full Text] [PDF]

				K. Bolar, A. R. Hoffman, T. Maneatis, and B. Lippe Long-Term Safety of Recombinant Human Growth Hormone in Turner Syndrome J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 344 - 351. [Abstract] [Full Text] [PDF]